

Produktinformation



Forschungsprodukte & Biochemikalien
Zellkultur & Verbrauchsmaterial
Diagnostik & molekulare Diagnostik
Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien T. +43(0)1 489 3961-0 F. +43(0)1 489 3961-7 <u>mail@szabo-scandic.com</u> www.szabo-scandic.com

Data Sheet (Cat.No.T19831)



Sodium Oxamate

Chemical Proper	ties	
CAS No. :	565-73-1	H ₂ N
Formula:	C2H2NNaO3	> 0
Molecular Weight:	111.03	0
Appearance:	no data available	` 0⊖
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year	Na ⁺

Biological Description	
Description	Sodium Oxamate (Oxamic acid sodium salt) is an LDH inhibitor that specifically inhibits LDHA. Sodium Oxamate has antitumor activity and induces cell cycle arrest and apoptosis.
Targets(IC50)	Apoptosis,Dehydrogenase,CDK
In vitro	 METHODS: Human lung cancer cells H1299, A549 and normal human bronchial epithelial cells HBE were treated with Sodium Oxamate (1-100 mmol/L) for 24 h. Cell viability was measured by CCK-8 assay. RESULTS: Sodium Oxamate significantly inhibited the cell viability of H1299 and A549 cells in a dose-dependent manner, with IC50 of 32.13±2.50 and 19.67±1.53 mmol/L, respectively. Sodium Oxamate had almost no effect on HBE cells, with an IC50 of 96.73 ±7.60 mmol/L. [1]. METHODS: Human lung cancer cells A549 and normal human bronchial epithelial cells HBE were treated with Sodium Oxamate (20-100 mmol/L) for 24 h, and several intracellular biochemical parameters were measured. RESULTS: LDH activity, ATP content and NADPH/NADP ratio were significantly decreased and ROS content was significantly increased in A549 cells after Sodium Oxamate treatment. In contrast, glucose metabolism was less affected, although LDH enzyme was also inhibited in a dose-dependent manner in HBE cells. [2]
In vivo	 METHODS: To detect the antitumor activity in vivo, Sodium Oxamate (300 mg/kg once a day) and pembrolizumab (10 mg/kg twice a week) were intraperitoneally injected into B-NDG mice carrying human lung cancer tumor H1299 for fifteen days. RESULTS: Both Sodium Oxamate and pembrolizumab significantly delayed tumor growth in monotherapy, and the combination therapy was more effective. [1] METHODS: To explore the potential for the treatment of diabetes, Sodium Oxamate (350-750 mg/kg) was administered intraperitoneally to db/db mice once daily for twelve weeks. RESULTS: Sodium Oxamate treatment reduced body weight gain, blood glucose and HbA1c levels, and improved insulin secretion, pancreatic islet morphology, and insulin sensitivity in db/db mice, primarily by inhibiting the production of tissue lactic acid. [3]
	sensitivity in db/db mice, primarity by initibiting the production of tissue factic acid. [5]

Solubility Information

A DRUG SCREENING EXPERT

Solubility	H2O: 16.67 mg/mL (150 mM) ,Sonication is recommended.	
	DMSO: Insoluble,	
	(< 1 mg/ml refers to the product slightly soluble or insoluble)	

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	9.0066 mL	45.0329 mL	90.0657 mL
5 mM	1.8013 mL	9.0066 mL	18.0131 mL
10 mM	0.9007 mL	4.5033 mL	9.0066 mL
50 mM	0.1801 mL	0.9007 mL	1.8013 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Su G, Liu J, Duan C, et al.Enteric coronavirus PDCoV evokes a non-Warburg effect by hijacking pyruvic acid as a metabolic hub.Redox Biology.2024: 103112.

Inhibitor • Natural Compounds • Compound Libraries • Recombinant ProteinsThis product is for Research Use Only• Not for Human or Veterinary or Therapeutic UseTel:781-999-4286E_mail:info@targetmol.comAddress:36 Washington Street,Wellesley Hills,MA 02481